CA050_01953

CA050_01953 is a humanized monoclonal antibody fragment (Fab') that dual-targets and neutralizes both interleukin-17A (IL-17A) and interleukin-17F (IL-17F). Developed by Derphartox, a spin-off venture of UCB, the compound was specifically engineered for topical delivery to treat inflammatory skin conditions such as psoriasis. By inhibiting the signaling of both IL-17A and IL-17F, CA050_01953 aims to suppress the cytokine-driven inflammatory cascade and keratinocyte hyperproliferation that characterize psoriatic plaques. Preclinical evaluations, including studies in human skin-SCID mouse transplant models, have demonstrated its ability to reduce epidermal thickness and inflammatory markers when applied topically, offering a potential localized alternative to systemic IL-17 inhibitors.